Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Larry Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Harrison Parsons - Stephens Margaret Kaczor - William Blair Joanne Wuensch - Citibank Rich Newitter - Truist Securities Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Hello, and welcome to Glaukos Corporation's Second Quarter 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
